The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

PURPOSE: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non–small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that...

Descripción completa

Detalles Bibliográficos
Autores principales: Weidhaas, Joanne B., Hu, Chen, Komaki, Ritsuko, Masters, Gregory A., Blumenschein, George R., Chang, Joe Y., Lu, Bo, Dicker, Adam P., Bogart, Jeffrey A., Garces, Yolanda I., Narayan, Samir, Robinson, Clifford G., Kavadi, Vivek S., Greenberger, Joel S., Koprowski, Christopher D., Welsh, James, Gore, Elizabeth M., MacRae, Robert M., Paulus, Rebecca, Bradley, Jeffrey D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566451/
https://www.ncbi.nlm.nih.gov/pubmed/37728512
http://dx.doi.org/10.1158/2767-9764.CRC-23-0084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566451/
https://www.ncbi.nlm.nih.gov/pubmed/37728512
http://dx.doi.org/10.1158/2767-9764.CRC-23-0084

Ejemplares similares